Published online before print May 10, 2007, doi: 10.1161/CIRCRESAHA.106.147256
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 10, 2006
Revised on April 3, 2007
Accepted on April 30, 2007
Inhibition of Progression and Stabilization of Plaques by Postnatal Interferon-
Function Blocking in ApoE-Knockout Mice
Mitsuhisa Koga ;
From the Department of Internal Medicine, Division of Cardiovascular Medicine (M. Koga, H.K., T.Y., Y. Kawai, K.K., T.I.), Kurume University; the Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences (M. Koga, T.Y., Y.K., M. Kai, Y. Kataoka), Fukuoka University; the Cardiovascular Research Institute (H.Y.) and the Department of Pathology (S.K.), Kurume University; and the Department of Cardiovascular Medicine (K.E.), Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
* To whom correspondence should be addressed. E-mail: naikai{at}med.kurume-u.ac.jp.
A role of interferon-
is suggested in early development of atherosclerosis. However, the role of interferon- in progression and destabilization of advanced atherosclerotic plaques remains unknown. Thus, the aim of this study was to determine whether postnatal inhibition of interferon- signaling could prevent progression of atherosclerotic plaques and stabilize the lipid- and macrophage-rich advanced plaques. Atherosclerotic plaques were induced in ApoE-knockout (KO) mice by feeding high-fat diet from 8 weeks old (w). Interferon- function was postnatally inhibited by repeated gene transfers of a soluble mutant of interferon- receptors (sIFNR), an interferon- inhibitory protein, into the thigh muscle every 2 weeks. When sIFNR treatment was started at 12 w (atherosclerotic stage), sIFNR not only prevented plaque progression but also stabilized advanced plaques at 16 w: sIFNR decreased accumulations of the lipid and macrophages and increased fibrotic area with more smooth muscle cells. Moreover, sIFNR downregulated expressions of proinflammatory cytokines, chemokines, adhesion molecules, and matrix metalloproteinases but upregulated procollagen type I. sIFNR did not affect serum cholesterol levels. In conclusion, postnatal blocking of interferon- function by sIFNR treatment would be a new strategy to inhibition plaque progression and to stabilize advanced plaques through the antiinflammatory effects.
Key words: atherosclerosis • inflammation • cytokine • gene therapy
Related Article:
-
Targeting Interferon- to Treat Atherosclerosis
- Israel Gotsman and Andrew H. Lichtman
Circ. Res. 2007 101: 333-334.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  H. Kudo, H. Kai, H. Kajimoto, M. Koga, N. Takayama, T. Mori, A. Ikeda, S. Yasuoka, T. Anegawa, H. Mifune, et al. Exaggerated Blood Pressure Variability Superimposed on Hypertension Aggravates Cardiac Remodeling in Rats via Angiotensin II System-Mediated Chronic Inflammation Hypertension, October 1, 2009; 54(4): 832 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider and H. S. Taatjes-Sommer Augmentation of Megakaryocyte Expression of Fc{gamma}RIIa by Interferon {gamma} Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1138 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kleemann, S. Zadelaar, and T. Kooistra Cytokines and atherosclerosis: a comprehensive review of studies in mice Cardiovasc Res, August 1, 2008; 79(3): 360 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gotsman and A. H. Lichtman Targeting Interferon-{gamma} to Treat Atherosclerosis Circ. Res., August 17, 2007; 101(4): 333 - 334. [Full Text] [PDF]
|
|